Research: Investigate FTC Warning Letters and Asahi’s Proprietary Ingredients

FTC Warning Letters and Asahi’s Proprietary Ingredients

The intersection of functional beverage innovation and regulatory oversight is defined by the tension between aggressive product marketing and the legal boundaries of health claims. As multinational conglomerates like asahi-group-holdings export proprietary functional ingredients such as lactobacillus-gasseri-cp2305 into Western markets, they must navigate a complex matrix of regulatory scrutiny. In the United States, the fda and ftc enforce strict substantiation requirements, aggressively policing the market through warning letters and legal actions against unsubstantiated health claims.

Regulatory Framework: Substantiating Functional Claims

In the United States, the regulatory oversight of dietary supplements and functional foods is divided between two primary agencies:

• The fda: Regulates labeling and safety, enforcing the boundaries of structure-function-vs-drug-claims. Ingredients must either be grandfathered in, undergo New Dietary Ingredient (NDI) notification, or achieve gras-generally-recognized-as-safe status [2].
• The ftc: Regulates advertising and marketing across all mediums.

The cornerstone of ftc enforcement is the requirement for competent-and-reliable-scientific-evidence to substantiate any health-related claims [2, 3]. According to the FTC’s Health Products Compliance Guidance, human clinical studies should ideally feature randomized, controlled testing (RCTs) with appropriate sample sizes, control groups (such as placebos), and clinically meaningful results [10]. Brands utilizing adaptogens and nootropics in functional beverages—such as kin-euphorics—generally face higher regulatory risks regarding their marketing rather than the legality of their formulations [3].

FTC Enforcement Actions & Warning Letters

The ftc and fda frequently issue joint warning letters to companies that cross the line from permissible structure/function claims into prohibited disease-treatment claims. For example, claims that adaptogens can mitigate, cure, or prevent COVID-19 have resulted in agencies classifying the offending products as “unapproved new drugs,” making them adulterated and misbranded under the FD&C Act [1].

Regulatory enforcement has expanded into broader marketing ecosystems:

• Influencer Disclosures: The ftc closely monitors social media, targeting wellness and functional food brands for failing to clearly disclose material connections. In 2023, the FTC issued a warning letter to the American Beverage Association and several registered dietitians regarding deceptive marketing practices on TikTok and Instagram [4].
• Dose-Insufficiency Litigation: Alongside federal regulators, a surge of consumer class-action lawsuits target functional/physiologic claims (e.g., “gut healthy,” nootropic benefits). Plaintiffs argue that the actual dosages in the beverages are too low to provide the advertised benefits, or that the presence of offsetting ingredients like sugar negates the health claims [5]. This highlights the ongoing clinical-substantiation-gap within the functional beverage industry.

Asahi’s Proprietary Ingredients: Lactobacillus gasseri CP2305

Amidst this rigorous regulatory environment, asahi-group-holdings has aggressively expanded its B2B functional ingredient portfolio. Its flagship proprietary lactic acid bacterium, lactobacillus-gasseri-cp2305, was derived from the legacy Calpis brand after years of research [7].

Scientific Claims and Commercialization

Scientific literature and clinical trials supported by Asahi indicate that CP2305 leverages the gut-brain axis to modulate the gut microbiome [6]. The claimed benefits include:

• Alleviation of daily mental stress and improved emotional well-being [6, 7].
• Enhancement of sleep depth and quality [7].
• Improvement of intestinal health [7].

In March 2025, asahi-group-foods began commercializing CP2305 globally outside the Asahi group, signing a strategic supply agreement with adm-wild-valencia to target food and beverage manufacturers in North America, Europe, and Asia [7]. The ingredient’s commercial viability was further validated in late 2025 when it won the “Functional Ingredient of the Year” at Gulfood Manufacturing in Dubai and the “Health Innovation Award” at Food Ingredients Europe [7].

However, in marketing the postbiotic B2B, distributors like ADM explicitly disclaim liability for consumer-facing claims, warning that manufacturers must ensure their final product claims align with local legislative requirements and scientific standards [6].

Global Regulatory Divergence: Japan vs. the United States

The regulatory pathway for ingredients like CP2305 differs vastly between Asahi’s domestic market and its Western expansion targets.

Japan’s Functional Food Framework

In Japan, japans-consumer-affairs-agency (CAA) governs health claims through three primary systems [11, 14]:

1. Foods for Specified Health Uses (FOSHU): Requires rigorous pre-approval by the government and clinical trials [11, 12, 15].
2. Foods with Nutrient Function Claims (FNFC): Allows standardized claims for recognized vitamins/minerals without pre-approval [11, 12].
3. Foods with Function Claims (FFC): Introduced as a more flexible route, FFC allows operators to label specific health benefits based on scientific evidence (via systematic literature reviews or clinical trials) without individual pre-approval from the CAA, placing the burden of responsibility on the business operator [11, 14, 15].

US Adaptation

When entering the US market, ingredients like Lactobacillus gasseri must pass fda safety thresholds. The FDA routinely processes gras-generally-recognized-as-safe notices for various Lactobacillus strains, issuing “no questions” letters that permit their use in conventional foods [9]. However, surviving FDA safety checks does not shield the final beverage brand from ftc substantiation requirements regarding the efficacy of the ingredient.

Contradictions & Gaps

• The Substantiation Paradox: There is a documented legal contradiction regarding the FTC’s demand for pharmaceutical-grade studies. While the FTC Health Products Compliance Guidance demands rigorous RCTs for health claims [10], federal courts have rebuffed FTC efforts to enforce these pharmaceutical standards on dietary supplements. In a landmark case involving Bayer’s Phillips Colon Health probiotics (which notably included a Lactobacillus gasseri strain), the court ruled that the FTC failed to prove that RCTs were the only way to satisfy the competent-and-reliable-scientific-evidence standard, aligning with FDA guidance that RCTs for supplements may not always be practical or ethical [8].
• Dose Dependency Gap: While Asahi possesses clinical trial data for CP2305’s efficacy [6], there is a gap regarding whether downstream B2B purchasers dose the postbiotic sufficiently in their final RTD beverages to legally survive FTC scrutiny or class-action lawsuits regarding dose-insufficiency [5].

Suggested Additional Sources

• FDA GRAS Database specific to CP2305: Search for the specific GRAS Notice number assigned to Asahi’s exact proprietary strain of Lactobacillus gasseri to verify its exact designated usage levels in US beverages.
• EFSA Novel Food Database: Investigate European Food Safety Authority rulings on CP2305 to determine how Asahi’s European distribution via adm-wild-valencia navigates the EU’s strict Novel Food and health claim regulations.
• Recent FTC Consent Orders: Review 2025/2026 FTC consent orders targeting probiotic and postbiotic claims to determine the exact threshold at which the FTC is currently prosecuting “gut-brain axis” marketing language.

References

1. Adaptogens & FDA/FTC Compliance: What You Need to Know — cohenhealthcarelaw.com
2. [PDF] Legal Framework for Adaptogens, Nootropics & Botanicals — acc.com
3. Frequently Asked Questions About Non-Alcoholic Beverage Regulations | Vicente LLP — vicentellp.com
4. [PDF] Warning Letter to American Beverage Association — ftc.gov
5. Food, Beverage, and Consumer Products Issues to Watch for 2026 — armstrongteasdale.com
6. [PDF] A Cutting Edge Solution - ADM — adm.com
7. Asahi Group’s Lactobacillus gasseri CP2305 Wins Functional Ingredient of the Year and Health Innovation Awards at Major International Exhibitions | Newsroom｜ASAHI GROUP HOLDINGS — asahigroup-holdings.com
8. Federal Court Rebuffs FTC Effort to Apply Pharmaceutical Standards to Dietary Supplement Substantiation - Rivkin Radler — rivkinradler.com
9. GRAS Notices — cfsanappsexternal.fda.gov
10. Health Products Compliance Guidance - Federal Trade Commission — ftc.gov
11. Japan: Food with Function Claims - RegASK — regask.com
12. [PDF] What are “Foods with Function Claims”? — caa.go.jp
13. FTC Policy Statement Regarding Advertising Substantiation — ftc.gov
14. The system of “Foods with Function Claims” has been … — caa.go.jp
15. Japan Health Food Regulation | ChemLinked — food.chemlinked.com